概述：噻氯匹定的药理学 - Suppr

Suppr

超能文献

Overview: pharmacology of ticlopidine.

作者信息

Gordon J L

出版信息

Agents Actions Suppl. 1984;15:108-15. doi: 10.1007/BF01966992.

DOI:10.1007/BF01966992

PMID:6385643

Abstract

摘要

相似文献

Overview: pharmacology of ticlopidine.

Agents Actions Suppl. 1984;15:108-15. doi: 10.1007/BF01966992.

Ticlopidine as an experimental antithrombotic agent.

Agents Actions Suppl. 1984;15:50-9. doi: 10.1007/BF01966961.

Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

Arq Bras Cardiol. 1983 Dec;41(6):425-7.

Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.

Agents Actions Suppl. 1984;15:68-75.

[Evaluation of platelet aggregation in patients treated with ticlopidine].

Clin Ter. 1984 Nov 15;111(3):247-50.

Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.

Thromb Res. 1985 Jan 1;37(1):29-43. doi: 10.1016/0049-3848(85)90030-1.

[The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].

Clin Ter. 1983 Feb 15;104(3):219-22.

Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.

Agents Actions Suppl. 1984;15:60-7.

[Changes of blood coagulability and effects of the platelet aggregation inhibitor (ticlopidine) in experimental subarachnoid hemorrhage in dogs].

Neurol Med Chir (Tokyo). 1985 Oct;25(10):810-7. doi: 10.2176/nmc.25.810.

In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets.

Agents Actions Suppl. 1984;15:97-104. doi: 10.1007/BF01966985.

引用本文的文献

Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Drugs. 1987 Aug;34(2):222-62. doi: 10.2165/00003495-198734020-00003.

本文引用的文献

EFFECTS OF BRADYKININ ON FOREARM VENOUS TONE AND VASCULAR RESISTANCE IN MAN.

Circ Res. 1965 Aug;17:106-13. doi: 10.1161/01.res.17.2.106.

Studies of components of the coagulation systems in normal individuals and septic shock patients.

Circ Shock. 1982;9(5):491-7.

Functional kallikrein inhibition during sepsis and bacterial shock.

Acta Chir Scand Suppl. 1982;509:39-41.

Inactivation of kallikrein in human plasma.

J Clin Invest. 1983 Jan;71(1):149-58. doi: 10.1172/jci110743.

New and rapid functional assay for C1 inhibitor in human plasma.

Blood. 1982 Apr;59(4):719-24.

Plasma kallikrein and Hageman factor in Gram-negative bacteremia.

Ann Intern Med. 1970 Oct;73(4):545-51. doi: 10.7326/0003-4819-73-4-545.

The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

J Immunol. 1968 Jun;100(6):1154-64.

Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.

J Clin Invest. 1973 Jun;52(6):1402-9. doi: 10.1172/JCI107313.

Kinin system responses in sepsis after trauma in man.

J Surg Res. 1974 Sep;17(3):147-53. doi: 10.1016/0022-4804(74)90101-2.

Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).

J Exp Med. 1974 Sep 1;140(3):797-811. doi: 10.1084/jem.140.3.797.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验